UK markets close in 9 minutes
  • FTSE 100

    5,737.64
    -54.37 (-0.94%)
     
  • FTSE 250

    17,595.26
    -258.04 (-1.45%)
     
  • AIM

    972.62
    -3.76 (-0.39%)
     
  • GBP/EUR

    1.1045
    +0.0024 (+0.22%)
     
  • GBP/USD

    1.3070
    +0.0049 (+0.38%)
     
  • BTC-GBP

    10,362.48
    +291.86 (+2.90%)
     
  • CMC Crypto 200

    269.33
    +8.04 (+3.08%)
     
  • S&P 500

    3,405.04
    +4.07 (+0.12%)
     
  • DOW

    27,638.08
    -47.30 (-0.17%)
     
  • CRUDE OIL

    39.46
    +0.90 (+2.33%)
     
  • GOLD FUTURES

    1,910.80
    +5.10 (+0.27%)
     
  • NIKKEI 225

    23,485.80
    -8.54 (-0.04%)
     
  • HANG SENG

    24,787.19
    -131.59 (-0.53%)
     
  • DAX

    12,084.89
    -92.29 (-0.76%)
     
  • CAC 40

    4,740.36
    -75.76 (-1.57%)
     

Pureos Bioventures closes first fund with USD 170 mn

·3-min read

EQS Group-News: Bellevue Asset Management AG / Key word(s): Funds/Private Equity
23.09.2020 / 07:00

Media release
Küsnacht, September 23, 2020

Pureos Bioventures closes first fund with USD 170 mn

Pureos Bioventures, a newly formed venture capital firm, advised by Bellevue Asset Management, announced the closing of its first fund BB Pureos Bioventures L.P. ("Pureos") with committed capital of USD 170 mn. Pureos will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell, and gene therapies. The fund's portfolio companies are built on scientific excellence with strong teams to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. The fund invests globally, with a primary focus on Switzerland and Europe. The Pureos team consists of experienced venture capitalists, biotech entrepreneurs, and drug developers.

For its first fund, Pureos is building a balanced portfolio of 15-20 pre-clinical and clinical-stage companies. Its initial investments include Alentis Therapeutics AG, AM-Pharma BV, Eyevensys SAS, Imcheck Therapeutics SAS, Lava Therapeutics BV, NovaGo Therapeutics AG, and Vico Therapeutics BV. Company building is an important part of Pureos. It is a Partner of BaseLaunch, a start-up accelerator in Basel and together with a team of Entrepreneurs-in-Residence, Pureos is working on translating ground-breaking science into novel companies.

Founding partners Klaus Breiner, Dominik Escher, and Martin Münchbach stated: "We are extremely pleased with the successful closing of our first fund. This would not have been possible without the trust and support of our investors to whom we are tremendously thankful. With the entrusted monies, we want to build and support great teams developing innovative therapeutics for devastating diseases that make a true difference for patients."

The supporters of the first Pureos fund include strategic limited partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, and family offices, institutional investors, and fund-of-funds.

For more information:
Bellevue Asset Management AG, Seestrasse 16 / Postfach, 8700 Küsnacht/Zurich
Tanja Chicherio, Tel. +41 44 267 67 09, tch@bellevue.ch

BB Pureos Bioventures
Dr. Klaus Breiner, Tel. +41 44 267 67 00, kb@bellevue.ch
Dr. Dominik Escher, Tel. +41 44 267 67 00, des@bellevue.ch
Dr. Anja Harmeier, Tel. +41 44 267 67 00, ahr@bellevue.ch
Dr. Martin Münchbach, Tel. +41 44 267 67 00, mam@bellevue.ch

www.pureosbio.com

About Pureos Bioventures
Pureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating, and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.

Disclaimer
The state of the origin of BB Pureos Bioventures L.P. (the "Fund") is Guernsey.
For Switzerland: The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is Quintet Private Bank (Schweiz) AG, Bahnhofstrasse 13, 8001 Zürich, Switzerland. In Switzerland, the Fund documents may only be distributed to qualified investors within the meaning of Art. 10 Para. 3, 3bis, and 3ter CISA. In respect of the units distributed in or from Switzerland, the place of jurisdiction is Guernsey. The basic documents of the Fund as well as the annual and the quarter-annual reports may be obtained free of charge at the registered office of the Swiss Representative.


End of Media Release

show this
show this